Genelux Corp (GNLX)
2.15
-0.11
(-4.87%)
USD |
NASDAQ |
Jun 26, 14:54
Genelux Debt to Equity Ratio: 0.00 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.0017 |
| June 30, 2023 | 0.0029 |
| Date | Value |
|---|---|
| March 31, 2023 | 0.6187 |
| December 31, 2022 | -0.6965 |
| September 30, 2022 | -0.7387 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.7387
Minimum
Sep 2022
0.6187
Maximum
Mar 2023
-0.116
Average
--
Median
Dec 2023
Debt to Equity Ratio Benchmarks
| Verastem Inc | -- |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.5332 |
| IGC Pharma Inc | 0.0152 |
| NovaBay Pharmaceuticals Inc | 6.294 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 24.68M |
| Total Liabilities (Quarterly) | 9.592M |
| Shareholders Equity (Quarterly) | 15.08M |
| Current Ratio | 2.717 |
| Net Debt Paydown Yield | 2.87% |